The nicotine pouch war just got a regulatory stamp — sort of. On June 30, 2026, the US Food and Drug Administration issued modified risk grant orders to Swedish Match USA for 20 ZYN nicotine pouch products, clearing them to be marketed with a very specific claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
Read that carefully, because the wording matters. This is not the FDA calling ZYN safe, nor is it approval as a smoking-cessation aid. It’s a narrow endorsement: adults who smoke and completely switch away from cigarettes are likely lowering their health risks. Anyone who keeps smoking or vaping alongside the pouches doesn’t get that benefit, and the agency explicitly advised non-tobacco users to stay away entirely.
The 20 products covered are the ones you’d expect — 10 ZYN flavors, each at two strengths. That lineup includes ZYN Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen, offered in 3 mg and 6 mg nicotine strengths. The pouches are all-white and made from plant-derived, tobacco leaf-free nicotine, with 15 per can (or 20 in ZYN Ultra).
Speaking of Ultra: ZYN Ultra launched in June 2026 with a softer, slightly moist material and higher 9 mg and 11 mg nicotine strengths. Note that those Ultra strengths sit outside the freshly authorized modified-risk lineup, which tops out at 6 mg.
ZYN, now part of Philip Morris International since 2022, carries a US$5.64 manufacturer’s suggested retail price in the States, though real-world pricing dips as low as US$3.49 for single cans bought online or from retailers.
The ruling arrives after the category had already exploded past regulators. A recent World Health Organization report pegged global nicotine pouch retail sales at 23.4 billion units in 2024 — up more than 50 percent year over year. That growth has public health officials nervous. The WHO has flagged the pouches’ “strong youth appeal and high addiction potential,” warning that products pitched to smokers are increasingly finding new, younger users through social media and influencer marketing.
The FDA’s own conditions reflect that unease. Bret Koplow, acting director of the FDA’s Center for Tobacco Products, framed the decision as giving “adult users clear, science-based information about the relative harms of tobacco products.” Swedish Match must track real-world usage and report back, and the modified risk order is valid for five years unless renewed or withdrawn.
The bottom line the agency keeps repeating: there is no safe tobacco product, and quitting all tobacco and nicotine remains the healthiest choice. Whether ZYN ends up steering smokers off cigarettes — or minting a fresh generation of nicotine users — is a question the paperwork can’t answer.
